Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAX-31 in Healthy Infants
NCT06720038Phase 2Active, not recruiting
- Sponsor
- Vaxcyte
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 2
01
Overview
A Phase 2 trial of VAX-31 in pneumococcal disease, sponsored by Vaxcyte. Started Nov 2024; status: active, not recruiting.
02
Drugs
VAX-31
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06720038.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06720038.